Stand Up To Cancer Awards Moffitt $2.67 Million to Study New Lung Cancer Immunotherapy

Thursday, October 12, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

The SU2C Catalyst™ grant will partner Moffitt with Bristol-Myers Squibb, Iovance and Prometheus Laboratories to develop adoptive T cell therapy for non-small cell lung cancer



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook